Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TECH | US
1.99
3.80%
Healthcare
Biotechnology
30/06/2024
24/04/2026
54.19
52.53
54.74
52.05
Bio-Techne Corporation together with its subsidiaries develops manufactures and sells life science reagents instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research diagnostics and cell and gene therapy such as cytokines and growth factors antibodies small molecules tissue culture sera and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products including controls calibrators and diagnostic assays for regulated diagnostics market exosome-based molecular diagnostic assays advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening oncology diagnostics molecular controls and research as well as instruments and process control products for hematology blood chemistry and gases and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis Minnesota.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
66.4%1 month
49.6%3 months
45.3%6 months
40.0%67.85
37.59
5.46
0.20
0.15
36.94
9.98
1.78
310.37M
8.60B
8.60B
0.45
22.44
-44.20
1.60
8.33
4.23
2.54
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
11.34
Range1M
11.91
Range3M
21.67
Rel. volume
1.02
Price X volume
106.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc | ARWR | Biotechnology | 73.91 | 9.19B | -0.66% | n/a | 137.39% |
| Axsome Therapeutics Inc | AXSM | Biotechnology | 185.96 | 8.93B | 1.77% | n/a | 186.48% |
| Halozyme Therapeutics Inc | HALO | Biotechnology | 65.36 | 8.28B | -1.85% | 20.39 | 529.73% |
| Krystal Biotech Inc | KRYS | Biotechnology | 272.52 | 7.83B | 1.67% | 45.48 | 0.92% |
| Cytokinetics Incorporated | CYTK | Biotechnology | 65.32 | 7.69B | -0.24% | n/a | 727.94% |
| Nuvalent Inc. Class A Common Stock | NUVL | Biotechnology | 104.5 | 7.37B | -3.26% | n/a | 0.00% |
| Vaxcyte Inc. | PCVX | Biotechnology | 59.49 | 7.36B | -2.11% | n/a | 1.29% |
| Repligen Corporation | RGEN | Biotechnology | 117.6 | 6.59B | 3.10% | n/a | 37.40% |
| Grifols S.A | GRFS | Biotechnology | 8.08 | 6.31B | 1.13% | 33.27 | 190.24% |
| Arcellx Inc. Common Stock | ACLX | Biotechnology | 115.03 | 6.18B | -0.02% | n/a | 15.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sirius XM Holdings Inc | SIRI | Broadcasting - Radio | 26.61 | 9.02B | -4.96% | 8.37 | -444.39% |
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 36.94 | 0.53 | Expensive |
| Ent. to Revenue | 9.98 | 3,967.00 | Cheaper |
| PE Ratio | 67.85 | 41.03 | Expensive |
| Price to Book | 5.46 | 15.55 | Cheaper |
| Dividend Yield | 0.45 | 2.20 | Poor |
| Std. Deviation (3M) | 45.26 | 72.80 | Lower Risk |
| Debt to Equity | 0.20 | -1.23 | Expensive |
| Debt to Assets | 0.15 | 0.25 | Cheaper |
| Market Cap | 8.60B | 3.66B | Market Leader |